Research programme: anti-interleukin-20 monoclonal antibody - Development Center for Biotechnology
Alternative Names: DCBPR 0801Latest Information Update: 30 Aug 2023
Price :
$50 *
At a glance
- Originator Development Center for Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 20 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Rheumatoid arthritis in Taiwan (unspecified route)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Taiwan